PF-07104091 as a Single Agent and in Combination Therapy

Study Summary

To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.

Conditions

Small Cell Lung Cancer Ovarian Cancer Breast Cancer

Interventions / Drugs

PF-07104091 monotherapy dose escalation PF-07104091 + palbociclib + fulvestrant PF-07104091 + palbociclib + letrozole PF-07104091 monotherapy dose expansion (ovarian)PF-07104091 monotherapy dose expansion (SCLC)PF-07104091 + Fulvestrant (post CDK4/6)PF-0704091 + Fulvestrant (post CDK4/6)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment154 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.190009+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.